Patiromer and Diet/hrQoL in Chronic Dialysis

PHASE3RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 8, 2025

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions
HyperkalaemiaChronic Kidney Disease Stage 3 and 4Dietary Intervention
Interventions
DRUG

Patiromer 8400 MG [Veltassa]

Randomized patients will receive one 8.4 g packet of patiromer per day or one identical packet containing a placebo. To minimize the possibility of interference with gastrointestinal absorption of other orally administered medications, administration of patiromer will be separated by at least 3 hours from other oral medicinal products. Throughout the whole study period, the study drug will be administered every day in the morning.

DRUG

Placebo

Randomized patients will receive one packet of placebo identical to that of patiromer. Following the same treatment sequence of patiromer, administration of the placebo will be separated by at least 3 hours from any other oral medicinal products. As for patiromer, the placebo will be administered every day in the morning.

Trial Locations (1)

24127

RECRUITING

Nephrology Unit, ASST Papa Giovanni XXIII, Bergamo

All Listed Sponsors
lead

Mario Negri Institute for Pharmacological Research

OTHER